[Current trends in pharmacotherapy of prostatic adenoma: role of a new alpha-adrenoblocker kamiren XL in the treatment of this disease].

The aim of our study was assessment of clinical efficacy and safety of a new alpha-adrenoblocker kamiren XL in patients with prostatic adenoma (PA) with or without acute retention of urine (ARU). Seventy PA patients were divided into two groups. Group 1 (n = 35) patients had no ARU. They received kamiren XL in a dose 4 mg/day for 1 month. Group 2 (n = 35) patients received the same doses of kamiren XL in addition to urethral catheterization for 3-7 days. In group 1 efficacy of the pharmacotherapy reached 91.4%. Overall symptoms score fell by 45.2% (from 18.5 +/- 6.9 to 10.2 +/- 5.9), quality of life--by 36.5% (from 3.7 +/- 1.5 to 2.4 +/- 1.4), volume of residual urine diminished by 54.9% (from 35.2 +/- 42.1 to 15.9 +/- 24.4 ml), Qmax rose by 37.7% (from 9.6 +/- 2.7 to 13.3 +/- 4.6 ml/s). Side effects (weakness--11.4%, vertigo--8.6%, sleepiness--5.7%) were registered in 5 (14.3%) patients. The drug produced significant changes neither in systolic, diastolic blood pressure nor heart rate. In group 2 urination resumed in 25 (71.4%) patients. Of them, 45.7% patients considered their voiding satisfactory, control ultrasound investigation detected that their residual urine was less than 50 ml while Qmax was over 5 ml/s. Difficulties in urination were experienced by 25.7% patients who demonstrated residual urine in the range 10-210 ml and Qmax under 5 ml/s. Side effects were seen in 14.3% patients. Thus, alpha-adrenoblocker kamiren XL (doxasozine retard) is a highly effective and safe drug for treatment of PA patients including those with ARU.

[An open randomized comparative trial of efficacy and safety of selective alpha-adrenoblocker setegis (terazosin) in therapy of patients with chronic bacterial prostatitis].

An open randomized comparative trial of setegis (terazosine) has shown good subjective and objective results in patients with chronic bacterial prostatitis. The drug is well tolerated and produces insignificant side effects. It is also demonstrated that combined therapy with alpha-adrenoblockers is more effective that monotherapy with antibacterial drugs in patients with bacterial prostatitis.

[Clinical efficacy and safety of terazosine (setegis) in patients with benign prostatic hyperplasia with concomitant cardiovascular diseases].

The aim of the study was assessment of clinical efficacy and safety of terazosine (setegis) in patients with benign prostatic hyperplasia (BPH) and concomitant cardiovascular disease. A total of 62 BPH patients with cardiovascular disease (ischemic heart disease, hypertension) having indications for alpha-adrenoblockers (mean age 74 +/- 11 years, 58-85) received terazosine in a dose 1-5 mg for 2 months. Clinical efficacy of terazosine was assessed by IPSS scale, residual urine, maximal voiding velocity. Safety of the drug was controlled by monitoring of arterial pressure, ECG, echo-CG. All the tests were made before therapy, on the treatment week 2, 4 and 8. The response was 90.3%. Overall symptoms score decreased by 37.0%, quality of life score rose by 23.8%. Amount of residual urine fell by 64.8%, maximal voiding velocity increased by 36.6%. Moderate effects of the drug (vertigo, weakness) occurred in 11.3% patients for 1 or 2 days after start of the therapy and were due to a moderate fall of arterial pressure in normotensive patients. Later artertial pressure stabilized, ECG registered no exacerbations of ischemic heart disease, no anginal attacks, no change in cardiac rhythm. Thus, terazosine (setegis) is effective and safe in BPH patients with cardiovascular disease. Pretreatment consultation of the cardiologist is desirable for correction of basic antianginal therapy.